Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BCAB | US
-0.15
-3.36%
Healthcare
Biotechnology
30/06/2024
13/04/2026
4.31
4.50
5.22
4.31
BioAtla Inc. a clinical stage biopharmaceutical company develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011 a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors non-small cell lung cancer (NSCLC) and ovarian cancer. It also develops BA3021 a CAB ADC for multiple solid tumor types including NSCLC melanoma and head and neck cancer; and BA3071 which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma NSCLC small cell lung cancer hepatocellular carcinoma melanoma bladder cancer gastric cancer and cervical cancer. BioAtla Inc. was founded in 2007 and is based in San Diego California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
123.3%1 month
131.0%3 months
152.8%6 months
155.2%-
-
2.85
0.05
0.02
0.31
134.37
-
-108.88M
208.33M
208.33M
-
-
-
31.60
-134.14
7.70
10.33
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
6.40
Range1M
6.40
Range3M
6.40
Rel. volume
1.03
Price X volume
212.72K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Arcturus Therapeutics Ltd | ARCT | Biotechnology | 8.46 | 228.78M | 1.20% | n/a | 11.94% |
| Verastem Inc | VSTM | Biotechnology | 5.66 | 227.78M | 6.59% | n/a | 104.63% |
| Alector Inc | ALEC | Biotechnology | 2.33 | 226.76M | -4.90% | n/a | 23.98% |
| Anika Therapeutics Inc | ANIK | Biotechnology | 14.89 | 220.32M | 0.88% | n/a | 13.35% |
| LogicBio Therapeutics Inc | LOGC | Biotechnology | 8.365 | 219.79M | 0.54% | n/a | 0.00% |
| Abeona Therapeutics Inc | ABEO | Biotechnology | 5.06 | 219.17M | 3.05% | n/a | 31.63% |
| MacroGenics Inc | MGNX | Biotechnology | 3.47 | 217.65M | -3.61% | n/a | 58.90% |
| Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 6.38 | 210.93M | 6.69% | n/a | 6.58% |
| Voyager Therapeutics Inc | VYGR | Biotechnology | 3.84 | 209.41M | 2.67% | 29.89 | 13.99% |
| IVVD | IVVD | Biotechnology | 1.72 | 205.44M | -2.27% | n/a | 0.48% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CPI Card Group Inc | PMTS | Building Products & Equipment | 17.89 | 199.61M | 2.64% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 9.99 | 160.41M | -0.70% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.69 | 99.62M | -0.67% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 5.85 | 95.29M | 4.09% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.6936 | 73.22M | -0.73% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.56 | 64.29M | 0.28% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.31 | - | Cheaper |
| Ent. to Revenue | 134.37 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.85 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 152.77 | - | Riskier |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 208.33M | - | Emerging |